Algert Global LLC Has $8.44 Million Stock Holdings in Johnson & Johnson $JNJ

Key Points

• Algert Global reduced its Johnson & Johnson position by 37.4% in the second quarter, selling 19,852 shares and retaining 33,237 shares worth approximately $8.44 million. Institutional investors own 69.55% of JNJ.
• Johnson & Johnson reported quarterly earnings and revenue above analyst expectations, with revenue up 6.6% year over year, and maintained 2026 EPS guidance of $11.60–$11.75. The company also declared a quarterly dividend of $1.34, or $5.36 annualized, yielding about 1.9%.
• Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating and a $272.83 target, but valuation and legal risks remain concerns after a sharp stock rally. Recent executive share sales and unresolved talc litigation add to near-term uncertainty.

Algert Global LLC lessened its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 37.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 33,237 shares of the company's stock after selling 19,852 shares during the quarter. Algert Global LLC's holdings in Johnson & Johnson were worth $8,441,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of JNJ. Flavin Financial Services Inc. lifted its holdings in Johnson & Johnson by 46.6% during the second quarter. Flavin Financial Services Inc. now owns 6,239 shares of the company's stock worth $1,584,000 after acquiring an additional 1,984 shares in the last quarter. GSG Advisors LLC grew its stake in shares of Johnson & Johnson by 4.8% during the 2nd quarter. GSG Advisors LLC now owns 9,956 shares of the company's stock worth $2,529,000 after acquiring an additional 460 shares in the last quarter. Asset One Wealth Management LLC increased its stake in Johnson & Johnson by 30.2% in the 2nd quarter. Asset One Wealth Management LLC now owns 5,168 shares of the company's stock valued at $1,277,000 after buying an additional 1,198 shares during the last quarter. Safeguard Investment Advisory Group LLC raised its holdings in Johnson & Johnson by 11.0% during the second quarter. Safeguard Investment Advisory Group LLC now owns 3,659 shares of the company's stock worth $929,000 after acquiring an additional 362 shares in the last quarter. Finally, Ally Financial Inc. bought a new stake in shares of Johnson & Johnson during the 2nd quarter worth approximately $3,302,000. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Analyst sentiment remains supportive. JNJ received an upgrade that helped it reach a new 12-month high, while the broader analyst view is rated “Moderate Buy.” UBS also began coverage, potentially increasing institutional attention. Johnson & Johnson Reaches New 12-Month High Following Analyst Upgrade Johnson & Johnson Receives Average Rating of Moderate Buy
• Positive Sentiment: Johnson & Johnson’s 64-year record of dividend growth remains a key support for income-oriented investors. Strong profitability and the company’s diversified healthcare portfolio help sustain the dividend despite competitive pressure on a major drug. Johnson & Johnson Is Boring Which Makes Its Dividend Nearly Perfect
• Neutral Sentiment: Management will discuss the business at the Deutsche Bank Healthcare Summit on September 17. The event could provide updates on pharmaceuticals, litigation and forward guidance, but it is not itself a change to earnings expectations. Johnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare Summit
• Negative Sentiment: Profit-taking and valuation risk are elevated after JNJ gained about 60% over the past year versus roughly 21% for the S&P 500. Analysts question whether the current price already discounts growth above management’s near-term outlook. Was JNJ Stock Rally Actually Its Own? Is Johnson & Johnson Stock Priced For More Growth Than It Has Guided?
• Negative Sentiment: An executive vice president sold 33,597 shares worth approximately $9.2 million, reducing his holdings by 56.9%. The sale may reinforce short-term concerns about insider conviction, although it does not change JNJ’s fundamentals. SEC insider transaction filing
• Negative Sentiment: An analyst lowered the FY2026 EPS forecast, adding pressure to expectations. Talc litigation also remains unresolved despite a proposed path toward settlement, while the Louisiana verdict continues to focus attention on legal liability and potential costs. Johnson & Johnson dividend and competition analysis

Johnson & Johnson Stock Performance

Shares of JNJ opened at $275.12 on Friday. The firm has a market capitalization of $663.01 billion, a P/E ratio of 31.88, a P/E/G ratio of 2.66 and a beta of 0.24. Johnson & Johnson has a 52 week low of $173.33 and a 52 week high of $281.07. The stock has a 50 day moving average price of $261.98 and a two-hundred day moving average price of $245.07. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, beating analysts' consensus estimates of $2.84 by $0.06. The company had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The company's revenue for the quarter was up 6.6% on a year-over-year basis. During the same quarter last year, the company earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Equities analysts forecast that Johnson & Johnson will post 11.61 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be paid a $1.34 dividend. The ex-dividend date is Tuesday, August 25th. This represents a $5.36 annualized dividend and a yield of 1.9%. Johnson & Johnson's dividend payout ratio (DPR) is 62.11%.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Scotiabank reiterated an "outperform" rating and set a $305.00 target price on shares of Johnson & Johnson in a research note on Thursday, July 16th. UBS Group initiated coverage on Johnson & Johnson in a research note on Wednesday. They issued a "buy" rating and a $320.00 price target for the company. Royal Bank Of Canada boosted their target price on Johnson & Johnson from $265.00 to $287.00 and gave the stock an "outperform" rating in a research note on Monday, July 13th. Johnson Rice reiterated a "buy" rating on shares of Johnson & Johnson in a research report on Monday, August 3rd. Finally, Argus set a $300.00 price target on Johnson & Johnson in a research report on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $272.83.

Insider Activity

In related news, EVP Kathryn E. Wengel sold 10,000 shares of the stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the completion of the sale, the executive vice president directly owned 114,288 shares of the company's stock, valued at approximately $27,560,551.20. This trade represents a 8.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the sale, the executive vice president owned 25,447 shares in the company, valued at $6,991,308.78. This trade represents a 56.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 97,569 shares of company stock worth $25,476,044. Corporate insiders own 0.16% of the company's stock.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.